Log in

OTCMKTS:STXSStereotaxis Stock Price, Forecast & News

+0.08 (+1.98 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $4.13
50-Day Range
MA: $3.64
52-Week Range
Now: $4.13
Volume304,723 shs
Average Volume265,430 shs
Market Capitalization$285.14 million
P/E RatioN/A
Dividend YieldN/A
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolOTCMKTS:STXS
Previous SymbolNASDAQ:STXS



Sales & Book Value

Annual Sales$29.35 million
Cash Flow$0.02 per share
Book Value($0.02) per share


Net Income$120,000.00


Market Cap$285.14 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive STXS News and Ratings via Email

Sign-up to receive the latest news and ratings for STXS and its competitors with MarketBeat's FREE daily newsletter.

Stereotaxis (OTCMKTS:STXS) Frequently Asked Questions

How has Stereotaxis' stock been impacted by COVID-19 (Coronavirus)?

Stereotaxis' stock was trading at $3.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STXS stock has increased by 9.3% and is now trading at $4.13. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Stereotaxis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stereotaxis.

When is Stereotaxis' next earnings date?

Stereotaxis is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Stereotaxis.

How were Stereotaxis' earnings last quarter?

Stereotaxis Inc (OTCMKTS:STXS) posted its quarterly earnings results on Tuesday, May, 5th. The medical equipment provider reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The medical equipment provider earned $5.76 million during the quarter. Stereotaxis had a negative return on equity of 1,456.01% and a negative net margin of 14.80%. View Stereotaxis' earnings history.

What price target have analysts set for STXS?

2 equities research analysts have issued 1-year target prices for Stereotaxis' shares. Their forecasts range from $5.00 to $6.00. On average, they expect Stereotaxis' stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price. View analysts' price targets for Stereotaxis.

Has Stereotaxis been receiving favorable news coverage?

Headlines about STXS stock have been trending somewhat negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stereotaxis earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutStereotaxis.

Who are some of Stereotaxis' key competitors?

What other stocks do shareholders of Stereotaxis own?

Who are Stereotaxis' key executives?

Stereotaxis' management team includes the following people:
  • Mr. David Leo Fischel C.F.A., CFA, CPA, CEO & Chairman (Age 32)
  • Mr. Martin C. Stammer, Chief Financial Officer (Age 39)
  • Mr. Kevin M. Barry, Chief Legal Officer, Corp. Sec. & Chief Compliance Officer
  • Dr. Gery Tomassoni M.D., FHRS, Chief Medical Officer
  • Dr. J. David Burkhardt, Chief Devel. Advisor

What is Stereotaxis' stock symbol?

Stereotaxis trades on the OTCMKTS under the ticker symbol "STXS."

Who are Stereotaxis' major shareholders?

Stereotaxis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (4.49%), Geode Capital Management LLC (0.35%), Essex Investment Management Co. LLC (0.35%), EAM Investors LLC (0.29%), UBS Group AG (0.17%) and Two Sigma Advisers LP (0.13%). View institutional ownership trends for Stereotaxis.

Which institutional investors are selling Stereotaxis stock?

STXS stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Squarepoint Ops LLC, and Essex Investment Management Co. LLC. View insider buying and selling activity for Stereotaxis.

Which institutional investors are buying Stereotaxis stock?

STXS stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Two Sigma Advisers LP, Sturgeon Ventures LLP, Morgan Stanley, Wells Fargo & Company MN, Geode Capital Management LLC, Jane Street Group LLC, and Citigroup Inc.. View insider buying and selling activity for Stereotaxis.

How do I buy shares of Stereotaxis?

Shares of STXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stereotaxis' stock price today?

One share of STXS stock can currently be purchased for approximately $4.13.

How big of a company is Stereotaxis?

Stereotaxis has a market capitalization of $285.14 million and generates $29.35 million in revenue each year. Stereotaxis employs 119 workers across the globe.

What is Stereotaxis' official website?

The official website for Stereotaxis is www.stereotaxis.com.

How can I contact Stereotaxis?

Stereotaxis' mailing address is 4320 FOREST PARK AVENUE SUITE 100, ST.LOUIS MO, 63108. The medical equipment provider can be reached via phone at 314-678-6100 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.